e-learning
resources
Milan 2017
Tuesday, 12.09.2017
Evolution or revolution in the treatment of asthma and allergies
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with high and low reversibility
M. Castro (St. Louis, United States of America)
Source:
International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Session:
Evolution or revolution in the treatment of asthma and allergies
Session type:
Thematic Poster
Number:
4018
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Castro (St. Louis, United States of America). Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with high and low reversibility. 4018
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
Source: ERJ Open Res, 6 (1) 00204-2019; 10.1183/23120541.00204-2019
Year: 2020
Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017
Cilomilast decreases exacerbations and maintains lung function in patients with poorly reversible COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 88s
Year: 2004
Both moderate and severe exacerbations accelerate physical activity decline in COPD patients
Source: Eur Respir J, 51 (1) 1702110; 10.1183/13993003.02110-2017
Year: 2018
Does inflammation decrease after recovery from severe exacerbation of COPD?
Source: Eur Respir J 2005; 26: Suppl. 49, 53s
Year: 2005
Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma
Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues
Year: 2017
Dupilumab sustains long-term OCS reduction in OCS-dependent asthma patients
Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials
Year: 2021
Predictors of severe exacerbations in patients with moderate and severe asthma
Source: International Congress 2018 – Determinants and monitoring of asthma control
Year: 2018
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV
1
in patients with severe persistent allergic asthma irrespective of age
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005
Distribution of biomarkers in severe asthma and severe uncontrolled asthma
Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research
Year: 2021
Impact of moderate and severe exacerbations in severe COPD patients
Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD?
Year: 2018
Severe exacerbations predict excess lung function decline in asthma
Source: Eur Respir J 2007; 30: 452-456
Year: 2007
Dupilumab improves asthma control and quality of life in children with uncontrolled persistent asthma
Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches
Year: 2021
The profile of poor ICS adherence in uncontrolled moderate to severe asthma.
Source: Virtual Congress 2020 – Advances in asthma treatment
Year: 2020
Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 242s
Year: 2002
Tiotropium reduces asthma exacerbations in asthmatic patients with persistent airflow obstruction uncontrolled despite treatment in accordance with guidelines
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012
Tiotropium reduces oral prednisone requirements while improving respiratory function in patients with severe persistent asthma
Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma
Year: 2016
A treatment regime based on induced sputum eosinophilia does not result in a reduction in exacerbations in refractory severe asthmatics
Source: Annual Congress 2008 - Severe asthma: a heterogeneous clinical entity
Year: 2008
Analysis of causes and quality of patients‘ treatment with often severe asthma exacerbations
Source: Eur Respir J 2007; 30: Suppl. 51, 72s
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept